# MYC Proto-Oncogene: B-HLH-LZ Structure, Transcriptional Networks, and Super-Enhancer Regulation


## Key Takeaways

- The MYC proto-oncogene encodes the c-Myc transcription factor, a B-HLH-LZ protein that heterodimerizes with MAX to bind E-box sequences (CACGTG) and regulate thousands of target genes involved in cell growth, proliferation, metabolism, and apoptosis.
- MYC dysregulation, through chromosomal translocations (e.g., t(8;14) in Burkitt lymphoma), gene amplification (common in breast, ovarian, and lung cancers), or enhancer hijacking, is a hallmark of numerous human cancers, driving tumor initiation and progression.
- MYC's transcriptional activity is tightly controlled by a complex regulatory network involving promoter architecture, multiple enhancer elements including super-enhancers, and extensive post-translational modifications (phosphorylation, acetylation, ubiquitination) that modulate its stability and function.
- MYC orchestrates a global transcriptional program by recruiting P-TEFb for elongation, histone acetyltransferases via TRRAP, and chromatin remodelers, leading to the upregulation of cell cycle regulators, ribosomal biogenesis factors, and metabolic enzymes.
- Targeting MYC is challenging due to its intrinsically disordered nature, but strategies include direct inhibitors like Omomyc (a dominant-negative mutant) and small molecules blocking MYC-MAX dimerization, as well as indirect approaches targeting upstream regulators like BET proteins (e.g., JQ1) or CDK7.
- MYC expression is induced by diverse signaling pathways including WNT/β-catenin, Notch, and growth factor receptor signaling, and its deregulation is implicated in non-cancerous conditions such as cardiac hypertrophy and inflammatory diseases.

---

## Executive Summary & Key Metadata

The MYC proto-oncogene encodes a master transcription factor (c-Myc) that coordinates cell growth, proliferation, metabolism, and apoptosis. As a basic helix-loop-helix leucine zipper (B-HLH-LZ) protein, c-Myc heterodimerizes with MAX to bind E-box sequences (CACGTG) across the genome, regulating thousands of target genes. MYC is among the most frequently deregulated oncogenes in human cancer, with alterations including chromosomal translocation, gene amplification, and enhancer hijacking. Its activity is tightly controlled at multiple levels—transcriptional, post-transcriptional, and post-translational—and its dysregulation contributes to tumor initiation, maintenance, and progression. This reference manual provides a comprehensive overview of MYC's genomic architecture, [protein structure](/knowledge/bioinformatics/protein-structure-biophysical-levels-folding), signaling networks, pathogenic mutations, viral interactions, and therapeutic targeting.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | MYC |
| UniProt Accession | P01106 |
| Representative PDB ID | 1NKP |
| Chromosomal Locus | 8q24.21 |
| Primary Molecular Function | Sequence-specific DNA binding transcription factor; regulates [RNA polymerase](/knowledge/bioinformatics/rna-polymerase-structure-transcription-mechanisms) II transcription |
| Disease & Pathology Associations | Burkitt lymphoma, multiple myeloma, neuroblastoma, breast cancer, colorectal cancer, hepatocellular carcinoma, and many others |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Chromosomal Context

The human MYC gene is located on the long arm of chromosome 8 at band q24.21, spanning approximately 7.5 kilobases of genomic DNA. The gene is oriented on the minus strand of the reference genome (GRCh38/hg38) and contains three exons, with the first exon being non-coding. The coding sequence begins in exon 2 and extends through exon 3, producing a protein of 439 amino acids with a molecular weight of approximately 49 kDa.

The genomic region surrounding MYC is notable for its complex regulatory architecture. The gene lies within a "gene desert" that contains multiple long-range enhancer elements, including the well-characterized MYC enhancer cluster located several hundred kilobases downstream. This region also harbors single nucleotide polymorphisms (SNPs) associated with susceptibility to various cancers, including colorectal, prostate, and breast cancer. The 8q24 locus is frequently amplified in multiple tumor types, and the amplification unit often includes not only MYC but also adjacent genes such as PVT1, which encodes a long non-coding RNA that can cooperate with MYC in tumorigenesis.

### 1.2 Promoter Architecture and Transcription Factor Binding Sites

The MYC promoter is one of the most extensively studied regulatory regions in the human genome. It contains two major transcription start sites (TSSs), designated P1 and P2, which are separated by approximately 160 base pairs. The P2 promoter is the dominant start site, accounting for 75–90% of MYC transcripts in most cell types. A third promoter, P0, is located further upstream and is used less frequently.

The promoter region contains multiple cis-regulatory elements that integrate diverse signaling inputs:

- **TATA box**: Located approximately 30 base pairs upstream of the P2 start site, recognized by the general transcription factor TFIID.
- **E2F binding sites**: Two E2F consensus sequences within the promoter mediate cell cycle-dependent regulation. E2F transcription factors activate MYC expression during the G1/S transition, while the retinoblastoma protein (Rb) represses MYC through E2F sequestration.
- **CT element**: A polypyrimidine/polypurine tract that can adopt non-B DNA conformations. This element is bound by both double-stranded DNA-binding proteins (e.g., Sp1) and single-stranded binding proteins (e.g., hnRNP K), and is required for optimal P1 promoter usage.
- **Nuclease-hypersensitive element (NHE)**: Located upstream of P1, this region contains binding sites for the zinc finger protein THZif-1 (also known as MAZ), which functions as a transcriptional repressor.
- **ME1a1 and ME1a2 elements**: These elements bind the transcription factor FUSE-binding protein (FBP), which activates MYC transcription, and FBP-interacting repressor (FIR), which suppresses it.
- **MDBP site**: A methylation-dependent binding protein site in the first intron that may contribute to transcriptional regulation.

### 1.3 Enhancer Elements and Super-Enhancer Regulation

MYC expression is controlled by a complex array of enhancer elements that respond to developmental and mitogenic signals. The most well-characterized enhancers include:

- **The MYC enhancer cluster (MEC)**: Located approximately 1.5 Mb downstream of MYC, this region contains multiple enhancer elements that loop to the MYC promoter. The MEC includes the rs6983267 SNP, which lies within an enhancer that binds TCF7L2/β-catenin and is associated with colorectal cancer risk.
- **Super-enhancers**: In embryonic stem cells, MYC is regulated by a super-enhancer that spans a large genomic region and is bound by core pluripotency factors including OCT4, SOX2, and NANOG. This super-enhancer is essential for maintaining MYC expression in self-renewing cells.
- **Tissue-specific enhancers**: Different cell types utilize distinct enhancer repertoires to control MYC expression. For example, B cells rely on the immunoglobulin heavy chain (IGH) enhancer, which becomes juxtaposed to MYC following chromosomal translocation in Burkitt lymphoma.

### 1.4 Alternative Splicing and Isoforms

The MYC gene produces multiple mRNA isoforms through alternative splicing and alternative promoter usage. The major transcript encodes the full-length c-Myc protein of 439 amino acids. However, several additional isoforms have been described:

- **MYC-2**: A shorter isoform initiated from an internal ribosome entry site (IRES) in the 5' untranslated region, producing a protein lacking the N-terminal 100 amino acids.
- **MYC-3**: An isoform generated by alternative splicing that removes part of exon 2, resulting in a protein with an altered N-terminus.
- **MYC-HEX1**: A naturally occurring splice variant that lacks exon 2 and encodes a protein with dominant-negative activity.
- **dMyc**: The Drosophila homolog, which shares conserved functional domains but differs in regulatory complexity.

Additionally, the MYC locus produces several antisense transcripts, including MYC-AS, which may regulate MYC expression through RNA interference or transcriptional interference mechanisms.

### 1.5 Chromatin Structure and Nuclear Organization

The MYC gene exhibits dynamic chromatin structure that correlates with its transcriptional activity. In quiescent cells, the MYC promoter is associated with repressive chromatin marks, including histone H3 lysine 27 trimethylation (H3K27me3). Upon mitogenic stimulation, these marks are replaced by activating marks such as histone H3 lysine 4 trimethylation (H3K4me3) and histone acetylation. The gene also associates with the nuclear matrix in an activation-dependent manner, with active transcription correlating with matrix attachment.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Domain Organization

The c-Myc protein is organized into several functionally distinct domains that span from the N-terminus to the C-terminus:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| Transactivation Domain (TAD) | 1–143 | Transcriptional activation; interaction with TRRAP, GCN5, TIP60 |
| Myc Box I (MBI) | 45–63 | Phosphorylation-dependent degradation; interaction with FBXW7 |
| Myc Box II (MBII) | 128–143 | Transcriptional activation; interaction with TRRAP |
| Nuclear Localization Signal (NLS) | 320–328 | Nuclear import |
| Basic Region (BR) | 355–368 | DNA binding |
| Helix-Loop-Helix (HLH) | 368–410 | Dimerization with MAX |
| Leucine Zipper (LZ) | 410–439 | Dimerization with MAX |

### 2.2 N-Terminal Transactivation Domain

The N-terminal TAD is intrinsically disordered in isolation but adopts structured conformations upon binding to partner proteins. This domain contains two highly conserved Myc boxes (MBI and MBII) that are essential for transcriptional activation. MBI contains the phosphorylation sites Thr58 and Ser62, which regulate protein stability. Phosphorylation of Ser62 by ERK or CDK1 stabilizes c-Myc, while subsequent phosphorylation of Thr58 by GSK3β creates a phosphodegron recognized by the E3 ubiquitin ligase FBXW7, targeting c-Myc for proteasomal degradation.

MBII mediates interaction with TRRAP, a component of multiple histone acetyltransferase complexes including GCN5 and TIP60. This interaction recruits histone-modifying enzymes to MYC target gene promoters, facilitating chromatin remodeling and transcriptional activation.

### 2.3 C-Terminal DNA-Binding and Dimerization Domain

The C-terminal region contains the B-HLH-LZ motif that mediates sequence-specific DNA binding and heterodimerization with MAX. The basic region (residues 355–368) makes direct contacts with the major groove of DNA, recognizing the E-box consensus sequence CACGTG. The HLH and LZ regions form an extended α-helical structure that mediates dimerization.

The crystal structure of the MYC-MAX heterodimer bound to DNA (PDB: 1NKP) reveals a parallel four-helix bundle in which the HLH regions of MYC and MAX intertwine, while the LZ regions form a coiled-coil that stabilizes the dimer. The basic regions of both proteins insert into the major groove, making base-specific contacts with the E-box sequence. The dimerization interface is characterized by extensive hydrophobic interactions and a network of salt bridges that confer specificity for heterodimer formation over homodimerization.

### 2.4 Post-Translational Modifications and Structural Consequences

c-Myc undergoes numerous post-translational modifications that modulate its activity, stability, and interactions:

- **Phosphorylation**: Multiple kinases phosphorylate c-Myc at distinct sites. In addition to Thr58 and Ser62, phosphorylation at Ser71 and Ser81 by CDK2 and other kinases regulates transcriptional activity.
- **Acetylation**: The histone acetyltransferase p300/CBP acetylates c-Myc at lysine residues in the TAD, enhancing protein stability and transcriptional activity.
- **Ubiquitination**: FBXW7-mediated ubiquitination targets c-Myc for proteasomal degradation, while USP28 and USP36 deubiquitinases remove ubiquitin moieties to stabilize the protein.
- **O-GlcNAcylation**: The TAD is modified with O-linked N-acetylglucosamine (O-GlcNAc) at Thr58, which competes with phosphorylation and affects protein stability.
- **Sumoylation**: SUMO conjugation at lysine residues in the TAD modulates transcriptional activity.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load MYC (PDB: 1NKP)](/tools/protein-structure-viewer?source=direct&pdbId=1NKP)

The interactive visualizer allows exploration of the MYC-MAX heterodimer structure, including the B-HLH-LZ domain architecture, DNA-binding interface, and dimerization surface. Users can rotate the structure, highlight specific residues, and examine the electrostatic surface properties that govern DNA recognition.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Regulation by MYC

MYC functions as a global transcriptional regulator that amplifies the expression of actively transcribed genes. The prevailing model proposes that MYC acts as a "universal amplifier" of transcription, binding to promoter-proximal regions of most active genes and enhancing transcriptional elongation. This amplification model is supported by chromatin immunoprecipitation sequencing (ChIP-seq) studies showing that MYC binds to thousands of genomic loci, with preferential occupancy at active promoters and enhancers.

MYC regulates transcription through multiple mechanisms:

1. **Recruitment of positive transcription elongation factor b (P-TEFb)**: MYC interacts with CDK9/cyclin T1, promoting phosphorylation of [RNA polymerase](/knowledge/bioinformatics/rna-polymerase-structure-transcription-mechanisms) II at Ser2 of the C-terminal domain, which stimulates transcriptional elongation.
2. **Interaction with histone-modifying complexes**: Through TRRAP, MYC recruits histone acetyltransferases (GCN5, TIP60) that deposit H3K9ac and H3K14ac marks at target gene promoters.
3. **Chromatin remodeling**: MYC recruits SWI/SNF and other ATP-dependent chromatin remodeling complexes to facilitate nucleosome displacement.
4. **Regulation of RNA polymerase III**: MYC also activates transcription of tRNA and 5S rRNA genes by RNA polymerase III, contributing to increased translational capacity.

### 3.2 MYC Target Gene Networks

Global mapping of MYC binding sites has identified a core set of target genes that mediate its biological functions. These include:

- **Cell cycle regulators**: Cyclins (CCND1, CCND2, CCNE1), CDKs (CDK4), and E2F transcription factors. MYC directly activates cyclin gene expression, promoting G1/S transition.
- **Ribosomal biogenesis factors**: Ribosomal proteins (RPL and RPS families), nucleolin, and nucleophosmin. MYC coordinates the expression of all components required for ribosome assembly.
- **Metabolic enzymes**: Glucose transporters (GLUT1, SLC2A1), glycolytic enzymes (LDHA, PKM2), and glutamine metabolism genes (GLS1). MYC drives the metabolic reprogramming characteristic of cancer cells.
- **Apoptosis regulators**: BIM (BCL2L11), p53 pathway components, and death receptors. MYC sensitizes cells to apoptosis through multiple mechanisms.
- **Stress response genes**: ATF3 and other stress-responsive transcription factors.

### 3.3 Signaling Pathways Regulating MYC Expression

MYC expression is induced by numerous mitogenic signaling pathways:

- **WNT/β-catenin pathway**: β-catenin/TCF complexes bind to MYC enhancers and activate transcription. This pathway is frequently activated in colorectal cancer, leading to constitutive MYC expression.
- **Notch pathway**: Notch intracellular domain (NICD) activates MYC transcription through RBPJ binding sites in the promoter. Notch signaling is essential for MYC expression in T-cell acute lymphoblastic leukemia.
- **Hedgehog pathway**: GLI transcription factors activate MYC expression in medulloblastoma and other Hedgehog-driven tumors.
- **JAK/STAT pathway**: Cytokine signaling through JAK/STAT activates MYC transcription in hematopoietic cells.
- **Estrogen receptor signaling**: Estrogen directly induces MYC expression in breast cancer cells through estrogen response elements.
- **TGFα/EGFR signaling**: TGFα induces MYC expression in ovarian cancer cells through MAPK and PI3K pathways.
- **Angiotensin II**: Induces MYC expression in vascular smooth muscle cells through protein kinase C and MAPK pathways.
- **Thrombopoietin**: Activates MYC through protein kinase C-dependent pathways in megakaryocytes.
- **Progesterone**: Rapidly induces MYC expression in the avian oviduct.
- **1,25-dihydroxyvitamin D3**: Suppresses MYC transcription in HL-60 promyelocytic leukemia cells, promoting differentiation.
- **Retinoic acid**: Suppresses MYC transcription through E2F element binding.
- **Glucocorticoids**: Regulate MYC transcription in P1798 lymphoma cells.

### 3.4 Regulatory Feedback Loops

MYC participates in multiple autoregulatory and feedback loops:

- **MYC-miR-144/451 axis**: The miR-144/451 gene locus negatively regulates MYC expression. Depletion of this locus activates and sustains MYC expression, contributing to B-lymphomagenesis.
- **MYC-TXNIP loop**: MYC represses TXNIP expression, which in turn limits MYC genomic binding. Loss of TXNIP expands MYC-dependent transcriptional programs.
- **MYC-p53 loop**: MYC activates p53 through ARF, and p53 induces apoptosis or senescence. Tumors frequently inactivate this pathway to tolerate MYC overexpression.
- **MYC-E2F loop**: MYC activates E2F transcription factors, which in turn activate MYC, creating a positive feedback loop that drives cell cycle progression.
- **MYC-MIZ1 repression**: MYC can repress gene expression by binding to MIZ1 and recruiting DNA methyltransferases or histone deacetylases to MIZ1 target genes.

### 3.5 Protein-Protein Interaction Networks

The MYC interaction network is extensive, with over 200 documented binding partners. Key interactions include:

- **MAX**: Essential heterodimerization partner for DNA binding and transcriptional activation.
- **MAD family proteins (MXD1-4)**: Compete with MYC for MAX binding and repress transcription.
- **MNT**: A MAX-interacting protein that represses MYC target genes.
- **TRRAP**: Scaffold for histone acetyltransferase complexes.
- **FBXW7**: E3 ubiquitin ligase that targets MYC for degradation.
- **P-TEFb (CDK9/cyclin T1)**: Promotes transcriptional elongation.
- **MIZ1**: Zinc finger protein that mediates MYC-dependent transcriptional repression.
- **WDR5**: Component of histone methyltransferase complexes that interacts with MYC.
- **p400/TIP60**: ATP-dependent chromatin remodeler that regulates MYC target gene expression.

### 3.6 MYC in Development and Differentiation

MYC expression is developmentally regulated, with high levels in proliferating embryonic tissues and low levels in differentiated cells. In Xenopus laevis, Xc-myc is expressed during early embryogenesis, with dynamic patterns that correlate with cell proliferation. The Hydra myc2 gene, a unique pre-bilaterian member of the MYC family, is activated during cell proliferation and gametogenesis, indicating the ancient evolutionary origins of MYC function.

In the immune system, MYC is essential for B cell proliferation and antibody responses. MYC expression is induced by B cell receptor signaling and CD40 ligation. MYC can also break B cell tolerance, contributing to autoimmune responses. In common variable immunodeficiency, failure of MYC expression in B cells is associated with impaired antibody production.

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Chromosomal Translocations

MYC was first identified through its involvement in chromosomal translocations in Burkitt lymphoma. The t(8;14)(q24;q32) translocation juxtaposes MYC with the immunoglobulin heavy chain (IGH) locus, placing MYC under the control of the IGH enhancer. Variant translocations include t(2;8)(p12;q24) and t(8;22)(q24;q11), which involve the immunoglobulin kappa and lambda light chain loci, respectively.

The breakpoints in MYC are heterogeneous and depend on the cell type and stage of B cell development. In sporadic Burkitt lymphoma, breakpoints occur within the first exon/intron, while in endemic Burkitt lymphoma, breakpoints are located further upstream. The translocation results in deregulated MYC expression that is no longer responsive to normal regulatory signals.

MYC translocations also occur in other B cell malignancies:

- **Diffuse large B cell lymphoma (DLBCL)**: MYC translocations occur in approximately 10% of cases, often as "double-hit" lymphomas with concurrent BCL2 and/or BCL6 translocations. The translocation partner gene determines survival outcomes.
- **Multiple myeloma**: MYC translocations involving the immunoglobulin loci occur in approximately 15% of cases.
- **B cell chronic lymphocytic leukemia (B-CLL)**: A t(8;12)(q24;q22) translocation juxtaposes MYC with a chromosome 12 coding region.
- **T cell acute lymphoblastic leukemia (T-ALL)**: t(8;14)(q24;q11) translocations involve the T cell receptor alpha chain locus.
- **B cell lymphoma with t(8;14)(q24;q11)**: A variant translocation involving the T cell receptor alpha chain gene.

### 4.2 Gene Amplification

MYC gene amplification is observed in numerous solid tumors:

- **Breast cancer**: MYC amplification occurs in 15–30% of cases and is associated with poor prognosis. A tumor suppressor gene on chromosome 1p32-pter controls MYC family gene amplification.
- **Colorectal cancer**: MYC amplification occurs in approximately 10% of cases.
- **Ovarian cancer**: MYC amplification is observed in 20–30% of cases.
- **Prostate cancer**: MYC amplification is associated with advanced disease.
- **Small cell lung cancer**: MYC family gene amplification (MYC, MYCN, MYCL) occurs in 15–30% of cases.
- **Hepatocellular carcinoma**: MYC amplification contributes to hepatocarcinogenesis.
- **Medulloblastoma**: MYC amplification is associated with the aggressive large cell/anaplastic variant.

### 4.3 Point Mutations and Sequence Variants

While MYC is not commonly mutated by point mutations, several recurrent mutations have been described:

- **Thr58 and Ser62 mutations**: These phosphorylation sites are mutated in Burkitt lymphoma and other B cell lymphomas. Mutations at these sites prevent FBXW7-mediated degradation, leading to MYC stabilization. Thr58 mutations are the most common MYC mutations in lymphoma.
- **MYC box II mutations**: Mutations in this region abolish transcriptional activation and transforming activity.
- **N-terminal truncations**: In some lymphomas, MYC proteins with N-terminal deletions that remove the MBI domain are produced, resulting in increased protein stability.

### 4.4 MYC Deregulation in Non-Malignant Diseases

MYC expression is also altered in non-malignant conditions:

- **Cholesteatoma**: The c-MYC protooncogene is overexpressed in cholesteatoma, an epidermoid cyst of the middle ear characterized by hyperproliferation.
- **Endometriosis**: c-MYC polypeptide expression is elevated in endometriotic tissue.
- **Cardiac hypertrophy**: MYC expression is induced during cardiac myocyte hypertrophy. Heart-specific inhibition of c-MYC attenuates cold-induced cardiac hypertrophy.
- **Portal hypertension**: MYC expression correlates with vascular smooth muscle cell proliferation in patients with portal hypertension.
- **Systemic lupus erythematosus (SLE)**: MYC expression is altered in peripheral blood mononuclear cells from SLE patients.
- **Meningiomas**: Enhanced MYC expression is observed in human intracranial meningiomas.
- **Benign prostatic hyperplasia**: MYC expression is elevated compared to normal prostate tissue.

### 4.5 MYC in Development and Regeneration

MYC plays important roles in developmental processes:

- **Embryonic development**: MYC expression shows cell-type-specific patterns during human embryonic development.
- **Limb regeneration**: MYC expression is enhanced during forelimb regenerative outgrowth in Xenopus laevis.
- **Corneal stromal cells**: MYC is expressed in primary cultures of human corneal stromal cells.
- **Sertoli cells**: Follicle-stimulating hormone transiently induces MYC expression in primary Sertoli cell cultures.
- **Vascular smooth muscle**: MYC expression is induced by angiotensin II and other growth factors.

### 4.6 MYC and Metabolic Reprogramming

MYC drives global metabolic reprogramming in cancer cells. In colorectal cancer, MYC-induced metabolic changes occur at the adenoma stage, before malignant transformation. MYC activates glycolysis, glutaminolysis, and nucleotide biosynthesis while suppressing oxidative phosphorylation. This metabolic reprogramming is essential for supporting the biosynthetic demands of proliferating cells.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Retroviral Insertional Mutagenesis

MYC was originally discovered as the cellular homolog of the v-myc oncogene carried by avian myelocytomatosis virus MC29. Retroviral insertion near MYC can activate its expression through promoter or enhancer insertion mechanisms. A retroviral promoter, but not enhancer, linked to MYC transforms embryo cells.

### 5.2 Human Papillomavirus (HPV) Interactions

In HeLa cells, HPV18 integrates near the MYC locus, and the integrated viral transforming genes are amplified together with 5'-flanking cellular sequences located near MYC. This integration may contribute to MYC deregulation in cervical cancer.

### 5.3 Epstein-Barr Virus (EBV)

EBV, which is associated with endemic Burkitt lymphoma, expresses latent membrane proteins and EBNA proteins that can induce MYC expression. EBV infection may cooperate with MYC translocations to promote B cell transformation.

### 5.4 Hepatitis B and C Viruses

HBV and HCV infections are associated with hepatocellular carcinoma, and MYC overexpression is frequently observed in virus-associated liver cancer. The viral proteins may activate MYC through multiple mechanisms, including activation of β-catenin signaling.

### 5.5 Human T-Cell Leukemia Virus Type 1 (HTLV-1)

HTLV-1 Tax protein activates MYC expression through NF-κB and other pathways, contributing to adult T-cell leukemia/lymphoma pathogenesis.

### 5.6 Kaposi's Sarcoma-Associated Herpesvirus (KSHV)

KSHV latent proteins can induce MYC expression in primary effusion lymphoma and other KSHV-associated malignancies.

### 5.7 Bacterial Interactions

While direct bacterial interactions with MYC are less well characterized, Helicobacter pylori infection is associated with gastric cancer and can induce MYC expression through activation of NF-κB and other signaling pathways.

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Challenges in Targeting MYC

MYC has historically been considered "undruggable" due to its intrinsically disordered structure and lack of a conventional small-molecule binding pocket. However, multiple strategies have been developed to target MYC directly or indirectly.

### 6.2 Direct MYC Inhibitors

- **Omomyc**: A dominant-negative MYC mutant that forms heterodimers with MYC and blocks its transcriptional activity. Omomyc has shown efficacy in preclinical models and is being developed for clinical use.
- **10058-F4 and 10074-G5**: Small molecules that bind to the MYC-MAX interface and inhibit heterodimerization.
- **MYC-siRNA and antisense oligonucleotides**: RNA-based therapeutics that reduce MYC mRNA levels.
- **Triplex-forming oligonucleotides**: Molecules that bind to the MYC promoter and inhibit transcription.

### 6.3 Indirect MYC Inhibitors

- **BET inhibitors (JQ1, I-BET151)**: Inhibit BRD4, which is required for MYC transcription at super-enhancers. BET inhibitors downregulate MYC expression in multiple cancer types.
- **CDK7 inhibitors (THZ1)**: Inhibit CDK7, which regulates MYC transcription and RNA polymerase II phosphorylation.
- **CDK9 inhibitors**: Block P-TEFb activity, reducing MYC-dependent transcriptional elongation.
- **PI3K/mTOR inhibitors**: Downregulate MYC translation through inhibition of cap-dependent translation.
- **Proteasome inhibitors (bortezomib)**: Stabilize FBXW7 and promote MYC degradation.
- **HDAC inhibitors**: Modulate MYC expression through chromatin remodeling.
- **Topoisomerase II inhibitors**: Induce DNA cleavage at MYC loci, which is associated with gene expression. Amsacrine and epipodophyllotoxins have differential effects on topoisomerase II cleavage in the MYC gene.
- **Genistein**: Inhibits MYC expression and proliferation in keratinocytes.
- **Tranilast**: Suppresses MYC expression in vascular smooth muscle cells.
- **Cytosine arabinoside (Ara-C)**: Reduces MYC overexpression in prolymphocytic leukemia.

### 6.4 MYC in Drug Resistance

MYC expression influences sensitivity to various chemotherapeutic agents. MYC overexpression can confer resistance to apoptosis-inducing agents, while MYC inhibition can sensitize cells to chemotherapy. The interferon-inducible p48 (ISGF3γ) gene is regulated by MYC, linking MYC to interferon signaling and drug resistance.

### 6.5 Clinical Trials and Therapeutic Development

Multiple clinical trials are evaluating MYC-targeting strategies:

- **Omomyc (OMO-103)**: A peptide inhibitor of MYC in Phase I/II clinical trials for advanced solid tumors.
- **BET inhibitors**: Several BET inhibitors are in clinical trials for hematologic malignancies and solid tumors.
- **CDK7 inhibitors**: SY-5609 and other CDK7 inhibitors are being evaluated in clinical trials.
- **Combination therapies**: MYC inhibitors are being combined with conventional chemotherapy, immunotherapy, and targeted agents.

### 6.6 MYC and Immunotherapy

MYC expression influences the tumor immune microenvironment. MYC-driven tumors often exhibit immune evasion through upregulation of PD-L1 and suppression of T cell infiltration. Targeting MYC may enhance the efficacy of immune checkpoint inhibitors.

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 4609 | https://www.ncbi.nlm.nih.gov/gene/4609 |
| Ensembl | ENSG00000136997 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136997 |
| UniProt | P01106 | https://www.uniprot.org/uniprotkb/P01106 |
| RCSB PDB | 1NKP | https://www.rcsb.org/structure/1NKP |
| Gene Ontology (GO) | GO:0001228, GO:0000978, GO:0005515 | https://www.ebi.ac.uk/QuickGO/ |
| ClinVar | Various | https://www.ncbi.nlm.nih.gov/clinvar/?term=MYC |
| COSMIC | MYC | https://cancer.sanger.ac.uk/cosmic |
| STRING | 9606.ENSP00000378674 | https://string-db.org/ |
| BioGRID | 112360 | https://thebiogrid.org/ |
| PhosphoSitePlus | MYC | https://www.phosphosite.org/ |
| TCGA | MYC | https://portal.gdc.cancer.gov/ |
| CCLE | MYC | https://portals.broadinstitute.org/ccle |

### Gene Ontology Terms

| **Category** | **GO Term** | **Description** |
|---|---|---|
| Molecular Function | GO:0001228 | DNA-binding transcription activator activity, RNA polymerase II-specific |
| Molecular Function | GO:0000978 | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
| Molecular Function | GO:0005515 | Protein binding |
| Biological Process | GO:0008283 | Cell population proliferation |
| Biological Process | GO:0006357 | Regulation of transcription by RNA polymerase II |
| Biological Process | GO:0045944 | Positive regulation of transcription by RNA polymerase II |
| Biological Process | GO:0006915 | Apoptotic process |
| Cellular Component | GO:0005634 | Nucleus |
| Cellular Component | GO:0000790 | Nuclear chromatin |

## 8. Mermaid Diagram: MYC Signaling and Regulation Network

```mermaid
flowchart TD
    A["Growth Factors"] --> B["Receptor Tyrosine Kinases"]
    B --> C["RAS/MAPK Pathway"]
    B --> D["PI3K/AKT Pathway"]
    C --> E["ERK"]
    D --> F["mTOR"]
    E --> G["MYC Transcription"]
    F --> H["MYC Translation"]
    
    I["WNT Signaling"] --> J["β-Catenin/TCF"]
    J --> G
    
    K["Notch Signaling"] --> L["NICD/RBPJ"]
    L --> G
    
    M["Estrogen Receptor"] --> G
    N["TGFα/EGFR"] --> G
    O["Progesterone Receptor"] --> G
    
    G --> P["MYC mRNA"]
    P --> Q["c-Myc Protein"]
    
    Q --> R["MYC-MAX Heterodimer"]
    R --> S["E-box Binding"]
    S --> T["Target Gene Activation"]
    
    T --> U["Cell Cycle Genes"]
    T --> V["Ribosomal Biogenesis"]
    T --> W["Metabolic Enzymes"]
    T --> X["Apoptosis Regulators"]
    
    Q --> Y["FBXW7 Degradation"]
    Q --> Z["TRRAP/HAT Complex"]
    
    AA["miR-144/451"] -->|"Inhibits"| G
    AB["TXNIP"] -->|"Limits"| R
    AC["p53"] -->|"Induces Apoptosis"| X
```

## 9. MYC in Cancer: Clinical and Pathological Considerations

### 9.1 MYC as a Prognostic Biomarker

MYC expression levels correlate with clinical outcomes in multiple cancer types. High MYC expression is associated with poor prognosis in breast cancer, colorectal cancer, ovarian cancer, and hematologic malignancies. MYC amplification status is used as a prognostic marker in medulloblastoma and neuroblastoma.

### 9.2 MYC and Tumor Heterogeneity

MYC expression is heterogeneous within tumors, with subpopulations of MYC-high cells exhibiting enhanced proliferative capacity. This heterogeneity may contribute to therapeutic resistance and disease recurrence.

### 9.3 MYC and Cancer Stem Cells

MYC is essential for maintaining cancer stem cell populations in various tumor types. MYC regulates self-renewal and differentiation programs, and MYC inhibition can deplete cancer stem cells.

### 9.4 MYC and Tumor Microenvironment

MYC expression in cancer cells influences the tumor microenvironment through secretion of cytokines, chemokines, and growth factors. MYC-driven tumors often exhibit an immunosuppressive microenvironment with reduced T cell infiltration and increased regulatory T cells.

### 9.5 MYC and Therapy Response

MYC status predicts response to various therapies:

- **Chemotherapy**: MYC overexpression is associated with resistance to certain chemotherapeutic agents.
- **Targeted therapy**: MYC amplification may predict sensitivity to BET inhibitors and CDK7 inhibitors.
- **Immunotherapy**: MYC-driven tumors may respond poorly to immune checkpoint inhibitors due to immune evasion mechanisms.

## 10. MYC in Non-Cancer Diseases

### 10.1 MYC in Cardiovascular Disease

MYC expression is induced during cardiac hypertrophy and vascular remodeling. Pressure overload induces MYC expression and reprogramming of cardiac gene expression. MYC inhibition attenuates cold-induced cardiac hypertrophy. In vascular smooth muscle cells, MYC mediates the proliferative response to angiotensin II and other growth factors.

### 10.2 MYC in Inflammatory Diseases

MYC expression is elevated in inflammatory conditions, including SLE and cholesteatoma. MYC may contribute to the hyperproliferative phenotype of inflammatory tissues.

### 10.3 MYC in Endometriosis

MYC expression is elevated in endometriotic tissue, suggesting a role in the pathogenesis of endometriosis.

### 10.4 MYC in Wound Healing and Regeneration

MYC is induced during tissue repair and regeneration. In Xenopus laevis, MYC expression is enhanced during forelimb regenerative outgrowth. MYC also plays a role in corneal wound healing.

## 11. Evolutionary Conservation and Comparative Genomics

### 11.1 MYC Family Evolution

The MYC gene family includes MYC, MYCN, and MYCL in vertebrates, which arose through gene duplication events. The Drosophila genome contains a single MYC homolog (dMyc), while Hydra contains two MYC genes (myc1 and myc2). The conservation of MYC across evolution underscores its fundamental role in cell biology.

### 11.2 Functional Conservation

The B-HLH-LZ domain is highly conserved across species, with near-identical DNA-binding specificity. The N-terminal TAD shows more divergence but retains conserved Myc boxes that are essential for function.

### 11.3 MYC in Model Organisms

- **Mouse**: MYC knockout is embryonic lethal, while conditional knockouts have revealed tissue-specific functions.
- **Zebrafish**: MYC is required for hematopoiesis and fin regeneration.
- **Drosophila**: dMyc regulates cell growth and proliferation.
- **X

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)